Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thermo-stable Flolan switch study in pulmonary arterial hypertension
NL-OMON35565Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epoprostenol in pulmonary arterial hypertension (PAH), sponsored by GSK. Primary endpoints: SF-36 quality of life questionnaire, Ease-of-use questionnaire and 1 more. Started Mar 2012; status: active, not recruiting.
02
Drugs
epoprostenol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON35565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35565.